Adaptimmune Therapeutics plc

What they do

Adaptimmune develops genetically modified autologous T-cell immunotherapies for solid tumor cancers. Its approved product, TECELRA (afamitresgene autoleucel), treats adults with unresectable or metastatic synovial sarcoma who are HLA-A*02 positive and whose tumors express MAGE-A4, under FDA accelerated approval based on overall response rate and duration of response. The company is selling TECELRA, lete-cel, afami-cel, and uza-cel to US WorldMeds and is seeking strategic options for remaining preclinical assets targeting PRAME and CD70.

Revenue drivers

• TECELRA product sales — Revenue from commercial sales of the approved synovial sarcoma cell therapy; Q2 2025 product revenue was $11.1 million from 16 patients invoiced, representing over 150% growth versus Q1 2025.
• Development activities revenue — Revenue from collaboration and development activities, which decreased 96% for the six months ended June 30, 2025 versus the prior-year period, primarily due to the April 2024 termination of the Genentech collaboration that had produced a $101.3 million cumulative catch-up adjustment in 2024.
• Sale of cell therapy assets to US WorldMeds — Definitive agreement to sell TECELRA, lete-cel, afami-cel, and uza-cel for $55 million upfront with up to $30 million in future milestone payments.

Recent performance

For the three and six months ended June 30, 2025, revenue was $13.7 million and $21.0 million, respectively, compared to $128.2 million and $133.9 million for the same periods in 2024, with the decline driven mainly by the prior-year Genentech catch-up adjustment. Q2 2025 TECELRA sales were $11.1 million with 16 patients invoiced, an increase of over 150% versus Q1 2025. Net loss attributable to ordinary shareholders was $30.3 million and $77.9 million for the three and six months ended June 30, 2025, compared to profits of $69.5 million and $21.0 million a year earlier. Cash and cash equivalents were $26.1 million as of June 30, 2025, down from $91.1 million at December 31, 2024.

Strategy

Following an extensive review of strategic alternatives, Adaptimmune entered a definitive agreement on July 27, 2025 to sell TECELRA, lete-cel, afami-cel, and uza-cel to US WorldMeds, which closed July 31, 2025. The company has repaid its debt facility with Hercules Capital and is restructuring to support the transferred assets and to maximize value from remaining assets, including PRAME-directed T-cell therapy ADP-600 and CD70-directed TRuC therapy ADP-520. It continues to seek strategic options for its preclinical assets and has paused spend on those programs. US WorldMeds intends to offer employment to approximately half of the company's existing employees.

Risks

• Going concern — The 10-K states that although financial statements were prepared on a going concern basis, there is substantial doubt about the company's ability to continue as a going concern.
• History of net losses — The company has incurred net losses every year since inception and expects to continue to incur net losses in the future.
• Dependence on successful commercialization — The company has never commercialized a product and its prospects depended on successful TECELRA commercialization, including operationalizing Authorized Treatment Centers and obtaining reimbursement.
• Listing-rule failures — Multiple 8-K filings since August 2025 report delisting notices or listing-rule failures, which could affect the liquidity and marketability of the company's ordinary shares and ADSs.

Outlook

Management states that following the US WorldMeds transaction and repayment of all sums under the Hercules Capital loan agreement, cash and cash equivalents are sufficient to meet planned operating requirements through the next 12 months. The company is restructuring to support the assets transferred to US WorldMeds and to maximize value from remaining PRAME and CD70 directed T-cell therapies. It continues to look for strategic options for its preclinical assets and has paused spend on them.